Bicycle Therapeutics PLC Sponsored ADR $BCYC Shares Sold by Siren L.L.C.

Siren L.L.C. reduced its position in Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) by 22.5% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 1,560,882 shares of the company’s stock after selling 451,870 shares during the period. Siren L.L.C.’s holdings in Bicycle Therapeutics were worth $7,242,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of BCYC. GSK plc purchased a new stake in shares of Bicycle Therapeutics during the fourth quarter worth about $10,829,000. Schroder Investment Management Group acquired a new stake in Bicycle Therapeutics during the 4th quarter valued at approximately $3,976,000. Woodline Partners LP purchased a new stake in Bicycle Therapeutics during the 1st quarter worth approximately $3,088,000. Birchview Capital LP increased its holdings in Bicycle Therapeutics by 200.5% during the 4th quarter. Birchview Capital LP now owns 462,700 shares of the company’s stock worth $3,276,000 after purchasing an additional 308,700 shares during the last quarter. Finally, Millennium Management LLC raised its position in shares of Bicycle Therapeutics by 156.5% in the 1st quarter. Millennium Management LLC now owns 453,428 shares of the company’s stock valued at $3,850,000 after purchasing an additional 276,671 shares in the last quarter. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Bicycle Therapeutics Stock Down 1.2%

BCYC stock opened at $4.16 on Friday. Bicycle Therapeutics PLC Sponsored ADR has a fifty-two week low of $3.92 and a fifty-two week high of $9.16. The firm’s 50-day simple moving average is $4.25 and its 200 day simple moving average is $5.03. The stock has a market cap of $290.41 million, a PE ratio of -1.32 and a beta of 1.55.

Bicycle Therapeutics (NASDAQ:BCYC) last posted its earnings results on Thursday, April 30th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.25). Bicycle Therapeutics had a negative net margin of 344.95% and a negative return on equity of 35.74%. The firm had revenue of $0.89 million for the quarter, compared to analyst estimates of $7.50 million. Equities analysts forecast that Bicycle Therapeutics PLC Sponsored ADR will post -1.97 EPS for the current fiscal year.

Insider Buying and Selling at Bicycle Therapeutics

In other news, CEO Kevin Lee sold 5,905 shares of Bicycle Therapeutics stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $4.27, for a total transaction of $25,214.35. Following the sale, the chief executive officer owned 605,408 shares of the company’s stock, valued at approximately $2,585,092.16. The trade was a 0.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 9,977 shares of company stock worth $42,702 over the last quarter. Insiders own 22.00% of the company’s stock.

Wall Street Analyst Weigh In

BCYC has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Bicycle Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 27th. Morgan Stanley reduced their price objective on shares of Bicycle Therapeutics from $13.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Wednesday, April 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Wednesday, July 8th. Jefferies Financial Group reissued a “buy” rating and issued a $12.00 target price on shares of Bicycle Therapeutics in a research report on Thursday, April 30th. Finally, Citigroup reiterated a “market outperform” rating on shares of Bicycle Therapeutics in a research note on Wednesday, June 3rd. Five investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $14.00.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.